Detalhe da pesquisa
1.
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
JAMA Oncol
; 3(7): 913-920, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27787547
2.
Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.
Cancer Epidemiol Biomarkers Prev
; 25(9): 1326-32, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27418270
3.
Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.
Urol Oncol
; 33(5): 204.e25-33, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25823535